[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335769-105":59,"doc-detail-335769-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","cost-effectiveness-of-trastuzumab-deruxtecan-in-patients-with-unresectable-or-metastatic-her2-low-breast-cancer-who-have-received-prior-chemotherapy","Cost-Effectiveness of Trastuzumab Deruxtecan in Patients with Unresectable or Metastatic HER2-Low Breast Cancer Who Have Received Prior Chemotherapy","","Economic evaluation estimates the cost-effectiveness of trastuzumab deruxtecan (T-DXd) for the EMA-approved indication in Denmark among patients with unresectable or metastatic HER2-low breast cancer who previously received chemotherapy. Clinical inputs come from the DESTINY-Breast04 (DB-04) trial and Danish resource and cost data are applied within a three-state partitioned survival model (progression-free, post-progression, death) over a lifetime horizon. T-DXd increases QALYs and yields an incremental cost-effectiveness ratio below the Danish willingness-to-pay threshold, with robustness shown via sensitivity and scenario analyses. The study concludes T-DXd is cost-effective versus physician’s choice.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cost-effectiveness-of-trastuzumab-deruxtecan-in-patients-with-unresectable-or-metastatic-her2-low-breast-cancer-who-have-received-prior-chemotherapy/335769/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cost-effectiveness-of-trastuzumab-deruxtecan-in-patients-with-unresectable-or-metastatic-her2-low-breast-cancer-who-have-received-prior-chemotherapy/335769.png","ImageObject",300,407,{"name":92,"@type":93},"Valentina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What treatment and patient population does the study evaluate in Denmark?","Question",{"text":113,"@type":114},"The study evaluates trastuzumab deruxtecan (T-DXd) for patients with unresectable or metastatic HER2-low breast cancer in Denmark who have received prior chemotherapy.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How is cost-effectiveness modeled in the evaluation?",{"text":118,"@type":114},"A three-state partitioned survival model is used, with states for progression-free, post-progression, and death, over a lifetime horizon, comparing T-DXd with physician’s choice.",{"name":120,"@type":111,"acceptedAnswer":121},"What are the main cost-effectiveness results?",{"text":122,"@type":114},"T-DXd gains 0.78 incremental QALYs and incurs DKK 621,325 in incremental costs versus physician’s choice, producing an incremental cost-effectiveness ratio of DKK 795,181 per QALY gained, which is below the willingness-to-pay threshold.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},335769,1790198142,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":41,"preview_page_count":14,"preview_urls":146},13056703020460,"https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","Adv Ther (2025) 42:322–333  \n[https://doi.org/10.1007/s12325-024-03033-2](https://doi.org/10.1007/s12325-024-03033-2)  \nORIGINAL RESEARCH  \nCost‑Effectiveness of Trastuzumab Deruxtecan in Patients with Unresectable or Metastatic HER2‑Low Breast Cancer Who Have Received Prior Chemotherapy  \nJeroen Hendrikus Jacobus Paulissen · Alexander Victor van Schoonhoven · Emma Olin · Arjan Jacobus Postma · Zacharie Mbanya · Kyle John Dunton · Maarten Jacobus Postma · Marinus van Hulst · Roel Donald Freriks  \nReceived: August 14, 2024 / Accepted: October 11, 2024 / Published online: November 12, 2024 © The Author(s) 2024  \nABSTRACT  \nIntroduction: In 2021, breast cancer affected 75,619 women in Denmark. Approximately 50% of breast cancers are considered human epidermal growth factor receptor 2 (HER2)-low. The DESTINY-Breast04 (DB-04) trial led to European Medicines Agency (EMA) approval of trastuzumab deruxtecan (T-DXd) as a treatment for patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed  \nSupplementary Information The online version contains supplementary material available at [https://doi.org/10.1007/s12325-024-03033-2](https://doi.org/10.1007/s12325-024-03033-2) .  \nJ. H. J. Paulissen (*) · A. V. van Schoonhoven ·  \nM. J. Postma · M. van Hulst  \nDepartment of Health Sciences, University Medical Center Groningen, Groningen, The Netherlands e-mail: [j.h.j.paulissen@umcg.nl](j.h.j.paulissen@umcg.nl)  \nJ. H. J. Paulissen · A. V. van Schoonhoven ·  \nA. J. Postma · R. D. Freriks  \nAsc Academics, Groningen, The Netherlands  \nE. Olin  \nAstraZeneca, Stockholm, Sweden  \nZ. Mbanya  \nAstraZeneca Plc., Cambridge, UK  \nK. J. Dunton  \nDaiichi Sankyo UK Ltd, Uxbridge, UK  \ndisease recurrence during or within 6 months of completing adjuvant chemotherapy. Moreover, the Danish Breast Cancer Group guidelines recently included T-DXd as a treatment for HER2-low metastatic breast cancer. This economic evaluation aims to estimate the costeffectiveness of T-DXd for the approved EMA indication in Denmark.  \nMethods: A three-state—progression-free, post-progression, and death—partitioned survival model was developed to estimate the costeffectiveness ofT-DXd versus treatment of physician’s choice over a lifetime horizon following the Danish Medicines Council guidelines. Clinical data were gathered from the DB-04 trial, and cost and resource use data were sourced from the  \nM. J. Postma  \nCenter of Excellence for Pharmaceutical Care Innovation, Universitas Padjadjaran, Bandung, Indonesia  \nM. van Hulst  \nDepartment of Clinical Pharmacy and Toxicology, Martini Hospital, Groningen, The Netherlands  \nR. D. Freriks  \nDepartment of Health Technology and Services Research, TechMed Centre, University of Twente, Enschede, The Netherlands  \nliterature. Sensitivity and scenario analysis were conducted to explore uncertainty.  \nResults: T-DXd led to 0.78 incremental qualityadjusted life years (QALYs) gained and incurred DKK 621,325 in incremental costs compared to the treatment of physician’s choice. This resulted in an incremental cost-effectiveness ratio of DKK 795,181 per QALY gained, which falls below the willingness-to-pay threshold. Sensitivity and scenario analyses showed the robustness of the deterministic result, with T-DXd remaining cost-effective.  \nConclusion: Our study demonstrates that T-DXd is a cost-effective treatment for patients with HER2-low unresectable or metastatic breast cancer who have received prior chemotherapy in Denmark.  \nKeywords: Cost-effectiveness; HER2-  \nlow; Metastatic breast cancer; Trastuzumab deruxtecan  \nKey Summary Points  \nThe results of the DESTINY-Breast04 (DB-04) trial led to a shift towards treating patients with breast cancer with a low level of human epidermal growth factor receptor 2 (HER2) expression (HER2-low) .  \nWe used an economic model with DB-04 survival using individual patient data to assess the cost-effectiveness of T-DXd in pati","cbCaid0m7EO0B1bX","https://ap.wps.com/l/cbCaid0m7EO0B1bX","pdf",851135,12,"English","# Abstract\n## Introduction\n## Methods\n## Results\n## Conclusion\n# Key Summary Points\n# Introduction","[{\"question\":\"What treatment and patient population does the study evaluate in Denmark?\",\"answer\":\"The study evaluates trastuzumab deruxtecan (T-DXd) for patients with unresectable or metastatic HER2-low breast cancer in Denmark who have received prior chemotherapy.\"},{\"question\":\"How is cost-effectiveness modeled in the evaluation?\",\"answer\":\"A three-state partitioned survival model is used, with states for progression-free, post-progression, and death, over a lifetime horizon, comparing T-DXd with physician’s choice.\"},{\"question\":\"What are the main cost-effectiveness results?\",\"answer\":\"T-DXd gains 0.78 incremental QALYs and incurs DKK 621,325 in incremental costs versus physician’s choice, producing an incremental cost-effectiveness ratio of DKK 795,181 per QALY gained, which is below the willingness-to-pay threshold.\"}]","Cost-Effectiveness of Trastuzumab Deruxtecan in Patients with Unresectable or Metastatic HER2-Low Breast Cancer Who Have Received Prior Chemotherapy | PDF",1790012258,[147,151],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/bee44ff4e3bbb3689e3b99d48f237b06.webp",983,1306,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/d8cb136b891b5aa7af0a4ec097064bed.webp",982,1304]